PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Bromocriptine”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,207 records · Page 67Linked to original sources

Bromocriptine-associated ototoxicity.

Three patients treated with bromocriptine for chronic hepatic encephalopathy showed audiometric evidence of bilateral sensori-neural hearing-loss. Audiometrically, the hearing improved in all three patients when the bromocriptine dosage was reduced, thus suggesting that this drug may produce a reversible ototoxicity.

Adult↗

Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine".

Since the initiation of bromocriptine therapy for Parkinson's disease several newer dopamine agonists have been developed. Pergolide has reached the stage of Phase 3 clinical trials and will probably be available for general use sometime in the foreseeable future. Lisuride shows most promise in its parenteral form for infusion therapy of patients with severe fluctuations. Mesulergine, another ergot-derivative and ciladopa, a new non-ergot agonist, have been withdrawn from further clinical use due to tumorogenesis in rats. It is questionable how applicable these findings are to the use of the drugs in elderly humans with parkinsonism. Recently a small number of drugs have been found to have postsynaptic dopamine agonist properties only in the setting of denervated supersensitive dopamine receptors. These agents may be particularly effective in the early treatment of patients with Parkinson's disease. This paper will review a number of the dopamine agonists which have been developed since the introduction of bromocriptine therapy. Several of these have shown beneficial effects in early clinical trials while others show promise in preclinical studies of animal models of parkinsonism.

Antiparkinson Agents↗

Effect of prolactin and bromocriptine on growth of transplanted hormone-dependent mouse mammary tumours.

Administration of ovine prolactin alone supported growth of hormone-dependent GR mouse mammary tumours. Growth of hormone-independent tumours was not stimulated. Furthermore, administration of bromocriptine, a compound that inhibits release of prolactin from the pituitary gland, was shown to inhibit the growth of hormone-dependent tumours in animals receiving treatment with progesterone + oestrone. Administration of prolactin or bromocriptine to mice bearing tumours that grew independently of progesterone + oestrone treatment had no influence on tumour growth. We conclude that direct as well as indirect evidence has been found for the involvement of prolactin in the growth of transplanted, hormone-dependent GR mouse mammary tumours.

Animals↗

Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.

Prolactinoma is the most frequent pituitary tumor histotype. Men generally have macroadenomas whereas women generally have microadenomas. The major objectives of treating prolactinomas are to suppress excessive hormone secretion and its clinical consequences, to remove the tumor mass while preserving the residual pituitary function, and possibly to prevent disease recurrence or progression. Primary therapy of prolactinomas is based on use of dopamine-receptor agonists. Bromocriptine induces normalization of prolactin levels in 80-90% of patients with microprolactinomas and approximately 70% of those with macroprolactinomas. Tumor-mass shrinkage and improvement of visual-field defects are found in the majority of treated macroprolactinomas, but bromocriptine often causes side effects. Cabergoline is very effective and well tolerated in more than 90% of patients with either microprolactinomas or macroprolactinomas. Cabergoline treatment also induces tumor shrinkage in the majority of patients with macroprolactinomas. Tumor shrinkage is more evident if patients have not previously been treated with other dopamine agonists. Fewer results are available for men than for women, but there is no evidence that men are less responsive to dopamine agonists than are women.

Adenoma↗

Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele.

Various types of alcoholics have been described and heredity has been shown to be involved in some of these types. An important role of the mesolimbic dopamine system has been suggested in the reinforcing effects of alcohol and recent molecular genetic studies are implicating the gene for the D2 dopamine receptor (DRD2) in alcoholism. In a double-blind study, bromocriptine, a DRD2 agonist, or placebo was administered to alcoholics with either the A1 (A1/A1 and A1/A2 genotypes) or only the A2 (A2/A2 genotype) allele of the DRD2 gene. The greatest improvement in craving and anxiety occurred in the bromocriptine-treated A1 alcoholics and attrition was highest in the placebo-treated A1 alcoholics. The feasibility of a pharmacogenetic approach in treating certain types of alcoholics is suggested.

Adult↗

Chronic bromocriptine treatment and glucose intolerance in acromegaly.

Blood glucose, plasma GH, insulin and glucagon levels during OGTT before and after treatment with bromocriptine (20 - 40 mg daily 3 - 18 months) were studied in 12 nondiabetic acromegalics (NA) and 6 diabetic acromegalics (DA) not treated previously. There was no significant change in blood glucose levels before and after treatment in NA while blood glucose levels fell significantly in DA after treatment. Mean basal GH levels and after OGTT decreased significantly in NA group, while only in the 120 min of OGTT in DA group. There was no significant change in mean basal or glucose stimulated plasma insulin or glucagon levels before and after treatment in both non-diabetic and diabetic acromegalics. Normal glucagon levels in diabetic acromegalics prior to treatment is considered as relative hyperglucagonaemia which disappeared after treatment. We did not show that glucagon suppressibility after OGTT was reestablished after treatment with bromocriptine in non-diabetic and diabetic acromegalics. Other factors than changes in hormones should be considered as a cause of restored glucose tolerance.

Acromegaly↗

Effect of bromocriptine administration during mid-pregnancy on the ovary function in the pig.

Plasma concentrations of prolactin, luteinizing hormone (LH), progesterone, estradiol-17 beta and androgens testosterone with dihydrotestosterone were determined in pregnant gilts (n = 6) administered bromocriptine (BR) from 37-42 days of pregnancy. Blood samples were daily taken at 2h-intervals from day 34 to 45 of pregnancy. BR treatment reduced (p less than 0.001) prolactin secretion from 14.8 +/- 0.9 ng/ml to 8.6 +/- 1.1 and 5.5 +/- 0.7 during the initial 1-3 and 4-6 days of treatment, respectively. Following cessation of BR treatment prolactin returned to the pre-treatment concentrations (14.5 +/- 1.0). BR did not alter LH during the first 3 days of treatment but decreased LH on days 4-6 (1.5 +/- 0.1 vs 2.1 +/- 0.2, p less than 0.05). Bromocriptine evoked a 20% increase (p less than 0.05) in estradiol-17 beta during days 1-3 following onset of treatment, however it suppressed androgen concentrations from 10.7 +/- 1.2 to 5.6 +/- 0.4 pg/ml in the same period. Suppression of prolactin from day 37-42 with a concurrent decrease of LH from day 40-42 of gestation did not affect maintenance of pregnancy and surprisingly was associated with a temporary elevation of progesterone. We conclude that prolactin has no luteotrophic properties during midpregnancy in gilts.

Animals↗

Quantitative pharmaco-electroencephalographic differentiation between the CNS effects of bromocriptine and imipramine, drugs with qualitatively different antidepressant properties.

Two double-blind, placebo-controlled studies were carried out at two different centers using the same protocol. Eight young healthy male volunteers were recruited for each of the studies, which were both undertaken to investigate the effect of single doses of 0.6, 1.25 and 2.5 mg bromocriptine (Parlodel) in comparison with 25 and 50 mg imipramine (Tofranil) on the electroencephalogram (EEG), subjective mental and emotional states, blood pressure, heart rate, and plasma prolactin levels. Side effects were also noted. The changes in the resting EEG power spectrum after imipramine were an increase in slow wave and fast beta activity and a decrease in alpha activity. At the same time imipramine depressed subjective mental and emotional states. Bromocriptine slowed the alpha activity of the resting EEG power spectrum, depressed subjective mental and emotional states, lowered blood pressure, and reduced prolactin secretion.

Adolescent↗

Metergoline and bromocriptine in the management of tumoral and idiopathic hyperprolactinemia.

59 patients affected by amenorrhea or anovulation, 37 of whom also with galactorrhea, and with hyperprolactinemia of unknown origin (idiopathic hyperprolactinemia, 24 patients) or due to a pituitary microadenoma (tumoral hyperprolactinemia, 35 patients) were treated with metergoline (4-12 mg/day) or with bromocriptine (2.5 to 10 mg/day) for 90 days. The effectiveness of the two treatments was assessed on clinical grounds and by evaluating at monthly intervals serum progesterone levels, during the presumed luteal phase, and serum prolactin levels. The success rate with the two drugs was superimposable in terms of disappearance of galactorrhea and return of menses, normalization of prolactin levels and induction of ovulation. Also the number of pregnancies obtained (7 with metergoline, 9 with bromocriptine) was similar. With both drugs, the majority of patients responded to the treatment within the first month.

Adenoma↗

[Bromocriptin in organic depression (author's transl)].

10 patients suffering from endogenomorphic depression on the basic of organic brain lesion were treated with 40 mg bromocriptin daily. Therapeutical efficacy was evaluated by various psychometric methods and by clinical impression. A negative correlation between performance and the depressive syndrome could be shown. Amelioration proved to be short lived, only 2 patients showed satisfactory response over a longer period of time. nausea and vomiting were the most common side effects, one patient showed a fully reversible manic syndrome. Reasons for the application of bromocriptin on the basis of a "dopamine-deficit hypothesis", and the results of the study are discussed.

Bromocriptine↗

Failure to induce ovulation with clomiphene citrate and bromocriptine in luteal deficient women athletes.

This study was designed with a three-fold aim: to assess ovarian function of women athletes with menstrual irregularities (AMI); to evaluate the potentiality of clomiphene citrate and bromocriptine for the induction of ovulation in these women; and to show that ultrasound scanning offers a suitable technique for ovarian screening in healthy and high-performance athletes. Our small test group consisted of 11 women, mainly track athletes, with AMI. There was no significant difference in age at menarche (13.2 yrs +/- 0.2), percent of ideal body weight (92% +/- 4), or percent of body fat (12.3% +/- 2.8) among the subjects. Plasma estradiol values were low (mean: 22 pg/ml +/- 0.8), as those of plasma progesterone (2.85 ng/ml +/- 2.10), LH (5.6 mIU/ml +/- 0.8), and prolactin (10.89 ng/ml +/- 5.56). The mean distance run per week (35 km +/- 15) was relatively high considering the presence of 4 non-runners. All menstrual irregularities were attributed to exercise. A short luteal phase (7 days +/- 1.5 for a cycle with a mean duration of 25 days +/- 1.8) was found in all subjects. We failed to observe the presence of a corpus luteum in 9 out of 11 women. A two-month administration of clomiphene citrate (150 mg/d for 5 days) or bromocriptine (2.5 mg/d) did not succeed in provoking ovulation in any of these women. Ultrasonographic observations showed a continuously hypo-estrogenic endometrium with a consecutively developing and regressive follicle. Our data emphasize the difficulties inherent in the restoration of menstrual function in women athletes with AMI. In addition, the usefulness of ultrasound in screening ovarian function was confirmed.

Adolescent↗

[Bromocriptine and tamoxifen--a new therapeutic approach in suppression-resistant prolactin-secreting adenomas].

In the present study the combination of tamoxifen and bromocriptine was tried for the suppression of prolactin in prolactin secreting adenomas which were resistant to suppression with bromoergocriptine alone. 10 women under treatment with 2.5-10 mg of parlodel (bromocriptine) for pituitary tumours of various sizes were additionally treated with tamoxifen 10-20 mg. (nolvadex) daily. Two patients had a previous incomplete resection for chromophobe adenomas. The other patients refused operation. Two women were also studied who did not tolerate a bromoergocriptine therapy because of side effects. In 6 of the 10 women with combination treatment a satisfactory suppression of the prolactin was observed. Four women were cleared of their amenorrhoea and galactorrhoea. One woman conceived. One woman lost her frigidity. Three women, among those the two with severe side effects from bromoergocriptine, tolerated the combined treatment well. Four women showed no success with the combined treatment. The effectiveness of the combined treatment was not correlated with the size of the tumour nor the clinical or biochemical baseline. The results lead to the conclusion that tamoxifen is capable of improving the suppression of prolactin or render the adenomas suppressible in a large number of cases.

Adolescent↗

[Treatment of Goldmann-Favre syndrome with cyclosporin A and bromocriptine].

Up to now several reports have described a disturbance of humoral and cellular immune response in patients with tapetoretinal degeneration, but a pathogenetic relation of the described immunological changes to the retinal disease was not established. Therefore immunosuppressive treatment has not been advocated for degenerative vitreoretinal disease. We now report about the natural course of Goldmann-Favre's vitreo-retinal degeneration and the results of a therapeutical trial with cyclosporin A and bromocriptine in two patients. Without therapy we saw a slowly progressive flat central retinoschisis with a serous macular exsudation in fluorescein-angiography. Additionally we found peripheral vitreoretinal changes, mild cellular vitreal infiltration, extinguished electro-retinogram and disturbed dark adaptation. Visual acuity and visual field were quite stabile. Under therapy with cyclosporin A we found a regression of the macular edema and flattening of the retinoschisis. One of the two cases showed a good improvement of visual acuity, in the other case a clear subjective improvement did not correlate with an increase in visual acuity. An additional therapy with bromocriptine did not bring further success, but we were able to reduce the cyclosporin A to a blood concentration of 70-100 ng per ml.

Adult↗

[Bromocriptin in the treatment of progressive stages of Parkinson's disease (author's transl)].

Forty patients with severe Parkinson's disease (23 men, 17 women) who had been treated for six years with L-dopa-decarboxylase inhibitor, were part of a placebo-controlled double-blind trial to test the effectiveness of bromocriptin. In all patients the effectiveness of L-dopa had been decreasing, 34 patients had L-dopa-induced dyskinesias, 35 "on-off" symptoms. Bromocriptin dosage was gradually increased to a total dose of 30 - 40 mg daily. This led to a 25% reduction in L-dopa requirements. The symptoms of Parkinson's disease were favourably influenced, with rigor, tremor and also walking disturbances responding better than bradykinesia of the hands. At the same time, there was a marked prolongation of the periods of good mobility ("on" time) from 7 to 10.8 hours without influence on other "on-off" symptoms such as paradoxical akinesia. Two patients had to be excluded from the trial because the treatment caused side effects (orthostatic hypotension, exogenous psychotic symptoms). Other side effects, such as nausea and mild forms of collapse, could be controlled by drugs.

Aged↗

Hysterectomy during the luteal period in dogs chronically treated with bromocriptine.

To determine whether prolactin has luteolytic properties during the first part of the luteal period, hysterectomy was performed in four dogs, in which prolactin had been chronically suppressed by bromocriptine administration. The concentration of progesterone in the peripheral blood decreased upon hysterectomy during the first part of the luteal phase and regained normal values after about seven days. The progesterone patterns during the perisurgical period in these dogs were similar to those patterns observed in dogs hysterectomised without bromocriptine treatment. It is concluded therefore that, in the dog, luteolytic properties can not be attributed to prolactin.

Animals↗

Effect of reserpine on the inhibition of prolactin released from different pituitary constructs in vitro by dopamine, bromocriptine and apomorphine.

Hourly release of Prolactin by pituitary constructs 1 whole pituitary (PI), adenohypophysis (P-N) and pituitary-hypothalamus co-incubate (PHC) were compared. Adenohypophysis secreted significantly more prolactin than PI and PHC, while PHC secreted significantly less than PI. Co-incubation of (P-N) with posterior pituitary reduced the elevated secretion of prolactin. Addition of dopamine (10(-7) M), bromocriptine (10(-7) M) and apomorphine (5 x 10(-8) M) to these constructs did not affect the release of prolactin from PI but inhibited the same from (P-N) and PHC. Treatment with reserpine increased serum prolactin levels but intrapituitary prolactin contents were decreased. Hourly release of prolactin from pituitary constructs derived from reserpine-treated rats was significantly reduced as compared to ascorbic acid--treated controls. Inclusion of dopamine (10(-7) M), bromocriptine (10(-7) M) and apomorphine (5 x 10(-8) M) in these constructs inhibited prolactin secretion further. In vitro addition of perphenazine stimulated the release of prolactin by PHC but was without any effect on PI and (P-N). The data are interpreted to suggest that dopamine in posterior pituitary may be an important determinant of hypothalamic modulation of prolactin secretion.

Animals↗

Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence.

Combinations of medications are often used in neuropsychiatry to enhance treatment efficacy. This 8-week, open-label study tested the combination of bupropion (< or =300 mg) and bromocriptine (< or =7.5 mg) daily in 34 cocaine-dependent (DSM-IIIR) outpatients also receiving weekly individual counseling. The first 18 subjects spent one week at maximum dose; the next 16 spent three weeks. Both groups showed significant reductions in self-reported cocaine use, with no significant change in proportion of urine toxicology tests positive for cocaine. There were no significant differences in outcome between groups. These results suggest that the combination of bupropion and bromocriptine is safe in cocaine addicts, but provide ambiguous evidence of its efficacy.

Adolescent↗